Liquidia Corp Stock - Sunday background on rare disease pipeline
Published on 06/21/2026 at 21:13 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 19:13 UTC. Details in the imprint.
Liquidia Corp (US53634H1077) develops therapies for rare cardiopulmonary diseases and has been on the radar of biotech investors after a recent earnings beat and ongoing work on pulmonary hypertension treatments, according to exchange data and analyst overviews.
Background and data on Liquidia Corp stock
Key figures, filings and news on Liquidia’s Nasdaq-listed stock can be found in the dedicated topic section and on the company’s investor-relations pages.
Recent earnings and business backdrop
Liquidia reported its most recent quarterly figures on 05/11/2026, delivering earnings per share of $0.52 versus a consensus estimate of $0.41, according to data compiled by MarketBeat. Revenue for the quarter reached $132.87 million, providing a tangible boost to fundamentals.
The same source indicates that the next earnings date is currently estimated for 08/11/2026, based on the company’s usual reporting rhythm rather than a formally confirmed calendar. For retail investors, that provisional date marks the next likely checkpoint for new guidance or pipeline commentary.
Sunday background on strategy and management
Liquidia positions itself as a biopharmaceutical company focused on developing, manufacturing and commercializing products for rare cardiopulmonary diseases, notably pulmonary hypertension. The company’s materials highlight a technology-driven approach to drug formulation aimed at improving delivery and patient outcomes.
Management has framed the strategy around leveraging its proprietary platforms and specialty-commercial footprint in pulmonary vascular disease, while continuing to expand clinical and regulatory work. Against this backdrop, governance and capital allocation decisions remain central for investors tracking long-term value creation.
How Liquidia makes its money
Liquidia’s core business model rests on developing and commercializing therapies for rare cardiopulmonary conditions in the United States, targeting areas such as pulmonary arterial hypertension and potentially related indications, as described in its corporate and analyst materials. Revenue is primarily driven by product sales and partnered programs in these specialty markets.
Where the stock trades today
Liquidia Corp stock (US53634H1077) most recently closed at $71.07 on Nasdaq on 06/18/2026, based on consolidated quote data.
Key facts on Liquidia Corp stock
- Company: Liquidia Corp
- ISIN: US53634H1077
- Ticker: LQDA
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 71.07 USD
- Market cap: 6.32 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Next earnings date: 08/11/2026 (estimated)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
